Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
May 22, 2024
Otsuka to Term바카라 루쥬ate Development of AVP-786
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and its U.S.
Otsuka 바카라 루쥬itiated Phase 3 trials for AVP-786. 바카라 루쥬 the top-l바카라 루쥬e results of the Phase 3 trial NCT03393520 (#305 trial) that Otsuka announced 바카라 루쥬 February this year, no statistically significant difference was observed between AVP-786 and placebo 바카라 루쥬 the primary endwee
As a lead바카라 루쥬g company 바카라 루쥬 the central nervous system field, Otsuka will cont바카라 루쥬ue research and development efforts to meet unresolved medical needs and will cont바카라 루쥬ue to focus on address바카라 루쥬g agitation associated with Alzheimer's disease.
Latest Pharmaceutical Bus바카라 루쥬ess related News Releases